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Abstract 
Cancer is a leading cause of death worldwide and a major public health 
burden. Technological advances in high-throughput genomic 
technologies now allow us to extract gene specific measurements at 
multiple levels, such as mutation, copy number alterations, gene 
expression to list a few. Genomic profiling of patient tumors have 
revealed massive heterogeneity in cancer, making it difficult to pin point 
the driver genes and translate this knowledge for clinical use. 
Alternatively, functional profiling based on RNA interference and drug 
sensitivity screens provide complementary information for 
understanding the functional relevance of genes related to cancer. Such 
screens can be used to chart the genetic vulnerabilities of cancer cells 
which can be useful in exploring therapeutic options. However, undesired 
off-target effects often complicate the interpretation of the results, and 
the consistency of these screens have been questioned. With the 
increasing availability of large-scale data on the molecular and functional 
characteristics of cancer cell lines, computational approaches are 
required to extract meaningful information from these datasets. Novel 
computational methods that are able to account for the complex 
biological mechanisms involved in RNA interference will improve the 
prediction of genetic vulnerabilities, and augment the discovery of novel 
biomarkers and targets for personalized treatment of cancer. 
In this work, I have developed and applied novel computational 
approaches for integration of large-scale genomic and functional 
datasets. Firstly, I developed an approach to remove noise from genome-
wide RNAi screens with the aim to increase their consistency. Further, I 
applied rigorous statistical analyses in multiple datasets to integrate 
mutational profiles with genome-wide RNAi screen data to predict novel 
synthetic lethal partners of major cancer driver genes that were 
experimentally validated by CRISPR/Cas9 knockout assay. Secondly, I 
explored the question of predictability of genetic dependencies by 
developing machine learning models using large-scale genomic datasets 
to reveal insights into gene dependencies that are more predictable, and 
identified the molecular features that contribute prominently to such 
predictions. Thirdly, I show the usefulness of performing computational 
analysis to identify a gene expression signature associated with cancer 
stemness, which predicts sensitivity of cancer cells to cancer stem cell 
 12 
inhibitors. Further, I show that the expression signature is useful in 
identifying patient sub-groups that will most likely benefit from the 
therapy. Altogether, the methods developed and applied in this work 
demonstrate clearly the usefulness of computational approaches to data 
integration in cancer cell line datasets. These findings advance current 
translational efforts for cancer therapy under the precision medicine 
paradigm. 
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1 Introduction 
Cancer is a deadly disease which inflicts havoc on the life of the individual 
diagnosed with it, also making the experience traumatic and emotionally 
overwhelming for individuals and families gripped by its influence. With 
14 million new cancer patients diagnosed yearly and approximately 9 
million deaths, cancer is the second leading cause of death worldwide (1). 
Although substantial progress has been made in terms of understanding 
its causes as well as development of prevention and treatment strategies 
(2), cancer remains a psychological, social and economic burden, and a 
major global health challenge (3). 
Cancer is an outcome of abnormal cellular growth, in which normal cells 
go awry and disobey the regular rules of tissue growth and differentiation 
that are necessary for maintaining tissue homeostasis, physiology and 
function. While normal cells behave in a disciplined manner and are 
programmed to work in unison with each other to guarantee survival of 
the organism, cancer cells have only one motive: make more copies of 
themselves (4). Although this nature of cancer was clear from early on, 
little progress had been made in terms of understanding the causes and 
the process of carcinogenesis. It was the discovery by Varmus and Bishop 
in 1976 (5), showing that genetic alterations in normal cells had the 
potential to transform them into cancerous cells, which provided the first 
coherent view that cancer is a genetic disease. From then on began the 
modern era of cancer biology, and massive strides have been made in 
gaining a molecular mechanistic understanding of cancer ever since. With 
this, also came the realization that cancer is dauntingly complex. 
In 2000, Hanahan and Weinberg distilled a giant body of scientific 
literature on the molecular studies of cancer and tumorigenesis into a 
generalized conceptual framework called ‘the hallmarks of cancer’ (6, 7). 
They overlayed the molecular and biochemical complexities of cancerous 
cells with the organizing principles of cellular physiology, and proposed a 
set of rules that underlie the transformation of normal cells to a 
malignant phenotype. These acquired capabilities of cancer cells:  
sustained proliferative signalling, resisting cell death, evading growth 
suppressors, limitless replicative potential, activation of invasion and 
metastasis, and sustained angiogenesis – served as a coherent template 
for making sense of the diverse molecular alterations present in cancer 
cells. They have also been very useful in interpreting the findings from 
Introduction 
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subsequent genomic studies that followed with the onset of genomic 
revolution, and has also ushered an era of targeted therapy for treatment 
of cancer patients (7). 
Post Human Genome Project the field of cancer genomics blossomed, and 
several large-scale projects were undertaken to systematically survey the 
frequency of genomic alterations in specific cancer types (8). These 
studies revealed frequent driver mutations of various kinase genes in 
melanoma, colon and lung cancer (9-12). Further, it was observed that 
several of the frequent kinase driver mutations were correlated with 
clinical responses to drug inhibition of the kinase activity (9, 10). These 
observations fortified the previous clinical success of the kinase inhibitor, 
imatinib mesylate, for treatment of chronic myeloid leukaemia (CML) 
patients having driving mutations in the BCR-ABL fusion gene, thus setting 
the stage for arrival of targeted cancer therapy (13, 14). The targeted 
therapy approach requires the identification of molecular targets crucial 
for the survival of cancer cells in a given genetic background, whose 
inhibition by a small molecule is expected to be highly selective to killing 
cancer cells with fewer side effects (13). This approach contrasts with the 
conventional approach of using chemotherapeutic agents that are 
relatively non-specific and yield considerable side effects.  
Spurred by the promise of targeted therapy began a quest to extensively 
characterize patient tumours (15-17). Big consortium projects such as The 
Cancer Genome Atlas (TCGA) (15) and International Cancer Genome 
Consortium (ICGC) (16) were launched for systematic genomic 
characterization of many cancer types, and are still ongoing. These 
massive efforts were aided by the maturation of sequencing technologies 
and the dawn of massively parallel sequencing (MPS), which made it 
possible to collect variety of genomic information with the same 
sequencing platform from a large collection of cancer patients (8). For 
instance, the MPS technology could be used in discovering point 
mutations, detecting copy number variations, quantifying transcript 
levels, and also in measuring DNA methylation. These studies were quite 
successful in discovering new driver genes and genetic alterations that 
have led to an improved molecular level understanding of the processes 
involved in cancer (8, 18).  
Contrary to the expectations based on the early success of inhibiting 
specific driver kinases, the genomic investigations did not reveal many 
recurrently mutated driver or druggable  cancer genes (8). Instead, the 
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sequencing studies made it clear that tumors generally harbor multiple 
genomically altered events, highlighting the incredibly complex landscape 
of genomic alterations and massive heterogeneity across cancer types, 
and even within the same tumor (18). Moreover, it became a challenging 
task to identify the genetic alterations that are relevant to cancer survival 
and growth, and also the presence of multiple genetic alterations 
mapping to several molecular processes, made it particularly difficult to 
pinpoint the druggable targets or pathways (18). Thus, the aspirations of 
targeted therapy are still beyond reach, with significant roadblocks in 
translating the genomic knowledge into clinically actionable treatment 
strategies. 
To fill the gap in the clinical translatability of the deluge of information 
obtained from the genomic studies, complementary strategies are 
needed to functionally characterize the variety of genes that are altered 
in cancer, so as to identify the ones relevant for cancer treatment (19-21). 
In vitro loss-of-function screens based on gene suppression using RNA 
interference (RNAi), or gene inactivation using the recently developed 
clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 
system have become widely-used techniques for interrogating the role of 
genes essential in various cancer types (21, 22). The ease of scalability of 
these genome perturbation techniques to high-throughput settings have 
allowed the examination of the functional roles of genes at genome-scale, 
thus making it possible to survey the gene essentiality landscapes in 
panels of cancer cells (23, 24). These techniques are also well suited for 
identifying promising drug-targets, because they mimic the desired effect 
of drug inhibitors, i.e., reduce the activity of the target protein product 
(22). Similarly, cell-based high-throughput drug sensitivity screens have 
also been developed to functionally assay the response of cancer cells to 
a library of small molecules, and are routinely being used to identify 
promising drug candidates and druggable genetic addictions of cancer 
cells (25-31).  
Several projects are being undertaken to extensively characterize the 
genomic and functional landscapes of a diverse panel of cancer cell line 
models from a wide variety of histological and tumor backgrounds (27, 
28, 30, 32-37). Since functional profiling and genomic profiling methods 
provide complementary information on the cancer cells, these datasets 
are extremely valuable resources for mining the links between the cancer 
genotype and phenotype. However, unlike the sequencing based-
Introduction 
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genomic technologies that are known to be quite robust, functional 
profiling techniques have several pitfalls. For instance, both RNAi and 
drug screens are known to suffer from off-target effects, and questions 
have been raised about the consistency and utility of these data for 
personalized medicine (38-40). Furthermore, the ‘big data’ nature of 
these datasets requires the application of sophisticated data analysis 
techniques and computational algorithms to extract knowledge with 
potential clinical applicability.  
The goal of this thesis is to develop and apply computational and 
analytical methods that can improve the estimation and prediction of 
genetic dependencies and druggable vulnerabilities in cancer cells. The 
ultimate objective is to identify genomic biomarkers potentially linked to 
effective targeted therapy of cancer. A wide variety of methodologies 
based on predictive machine learning models, unsupervised clustering, 
survival analysis and statistical methods are applied for the analytical 
settings considered in this work. These systems medicine approaches are 
expected to become important for the emerging translational efforts 
built on the concepts of personalized medicine and precision oncology. 
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2 Review of the literature 
2.1 RNA interference 
RNA interference (RNAi) is a phenomenon of RNA mediated gene 
silencing. It was first observed in C. elegans when long double-stranded 
RNAs (dsRNA) introduced into the organism led to the cleavage of mRNA 
transcripts with identical sequences (41). Following this discovery, RNAi 
very quickly became a powerful and widely used tool for genetic screens 
by gene knockdown. Later studies revealed that several types of RNA 
molecules could also trigger RNAi, such as RNA viruses, transposons and 
microRNAs (miRNAs) (42). Moreover, exogenously introduced chemically 
synthesized short RNA duplexes; also called short-interfering RNAs 
(siRNAs), or endogenously expressed hairpin RNAs; also called short-
hairpin RNAs (shRNAs), are also capable of inducing gene silencing (41). 
The discovery of the RNAi pathway has led to a fundamental shift in the 
understanding of how post-transcriptional gene regulation is achieved in 
eukaryotic systems. RNAi is known to have important biological functions; 
for instance, RNAi mediated by dsRNAs plays a major role in viral immunity 
in plants (41, 43). In addition, RNAi triggered by miRNAs, endogenously 
expressed non-coding RNAs, play an important role in regulation of gene 
expression during animal and plant development (41, 43). 
Although RNAi was recognized early on as a widespread phenomenon, 
present in both plants and animals, its application to mammalian systems 
revealed that long dsRNAs mediated RNAi triggers the activation of 
cellular immune response, eventually leading to cell death (44). Further 
biochemical investigations on the mechanistic underpinnings of RNAi 
machinery in different organisms revealed that short duplex siRNAs are 
capable of inducing gene knockdown in mammalian cells without 
activating the immune response (44). Chemically synthesized siRNAs that 
are transfected into cultured cells or shRNAs expressed by genomically 
integrated viral expression cassettes, are processed by an RNase III 
enzyme, Dicer, to yield duplex siRNA molecules (Figure 1). siRNAs, usually 
~21-23 nucleotides long are the effector molecules of RNAi machinery, 
which ultimately causes target gene suppression by degrading its mRNA 
(44). However, unlike the effector siRNAs derived from shRNAs or 
synthetic siRNAs; the effector siRNAs derived from miRNAs do not induce 
mRNA cleavage and rather repress protein translation by binding to the 3’ 
UTR of target mRNA (42).  
Review of the literature 
18 
 
 
 
 
Figure 1: RNAi mechanism of action. Target mRNA and virally tranduced shRNA 
expression cassettes integrated in the genome are transcribed from their respective 
promoters. The mRNA product from the shRNA expression cassettes form hairpin 
structures that are processed further into double-stranded short interfering RNAs 
(siRNAs). Only one of the strands of the duplex siRNA, known as the ‘guide’ strand or the 
‘antisense’ strand, is then loaded into a catalytic unit, called RNA-induced silencing 
complex (RISC). The guide strand serves as a template for guiding the RISC complex to 
target mRNAs based on sequence complementarity and induce its cleavage in a 
processive cycle, thereby inhibiting protein translation from the target mRNAs. Adapted 
from Mohr et al. (45).  
2.2 Clustered regularly interspaced short palindromic repeat 
(CRISPR)/Cas9 
CRISPR systems were originally thought to be similar to RNAi (46), and 
were first discovered in E. coli (47). Later it was recognized that they play 
an important role also in immunity to viruses (48). When bacteria are 
exposed to viral or foreign genetic material, short fragments of their DNA 
are incorporated in the host genome at CRISPR locus separated by a 
conserved repetitive element (48, 49). Transcripts that are generated 
from a CRISPR locus are processed by CRISPR-associated (Cas9) 
nucleases into short CRISPR-derived RNAs (crRNAs) that are 
AAAA
Target gene shRNA
Nucleus
Cytoplasm
RISC
AAAA
Long dsRNAs
AAAA
RISC
siRNAs (21bp)
Target mRNA cleavage
Nuclear export
Transcription
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complementary to the previously exposed foreign DNA material. The 
crRNAs assemble with Cas proteins to form large complexes that 
functions as an adaptive immune system in the bacteria, sensing and 
cleaving any foreign genetic material in the intracellular environment. 
Later it was realized that the sequence specificity of the crRNA/Cas9 
ribonucleoprotein complexes and the ability of Cas protein to create 
double strand breaks in the DNA can be exploited to conduct genetic 
perturbations of human cells (49). Cas9 can be targeted to specific 
genomic loci using a ‘guide’ RNA, which recognizes the target DNA and is 
able to induce mutagenesis by DNA double-strand break repair pathway. 
Short single guide RNA (sgRNA) that is complementary to the target DNA 
is often being used to target the Cas9 nuclease to a desired location in the 
genome. A sgRNA is typically 20-bp in length and also contains a 3-bp 
proto-spacer adjacent motif (PAM) after the 20bp region. The cleavage of 
target DNA, typically a coding region of gene, is induced by the Cas9 
nuclease, and loss-of-functions or indels are introduced by the non-
homologous end-joining mediated double stranded break repair pathway, 
creating a knockout of the targeted gene (49). 
2.3 Genome-wide RNAi screens 
The ability to ectopically introduce RNAi agents into cells, and the ease of 
scalability of the technique to high-throughput settings, has made it 
possible to perform high-throughput loss-of-function screens, radically 
enhancing the utility of RNAi to explore a variety of research questions 
(50, 51). Post human genome project era, the availability of complete 
human genome sequence has allowed the designing of libraries of RNAi 
agents to conduct genome-wide RNAi screens in human cultured cells and 
cancer cell lines (24, 52). RNAi screens can be performed in human cells 
either using synthetic siRNAs that are introduced by transfection, or 
using shRNAs that are expressed from vectors integrated into the host-
cell genome. However, the issue of transient gene silencing due to short 
life of siRNAs inside the cell, the difficulty of efficient transfectional 
delivery especially to primary cells, and the expensive cost of chemically 
synthesizing siRNAs, has limited their use in genome-scale screens (52).  
shRNA-based screens circumvent these problems by using expression 
cassette vectors that can be stably integrated into the host-cell genome 
of various cell types using lentiviral or retroviral transduction (44). These 
expression cassettes have promoters that drive the synthesis of shRNA 
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molecules, forming a hairpin structure with 19–29 bp (stem connected by 
a 6-9 bases long loop, that are processed to generate effector siRNAs (44). 
This provides a stable and renewable source of siRNAs making it possible 
to study the phenotypic effects of prolonged periods of gene 
suppression. Moreover, shRNA vectors are amenable to pooled 
’barcode’ screens that are less labor intensive, cheap and easily scalable 
in comparison to plate-based array screens (52, 53). Several shRNA 
libraries are available commercially with varying coverages of the number 
of genes that can be screened (24, 52). For example, The RNAi Consortium 
(TRC) library covers ~80% of the human coding genes, with an average of 
six unique shRNA clones per gene. The clones consist of hairpin sequences 
that are designed based on sequence composition, specificity, and 
position scoring to increase the likelihood of target gene knockdown (24). 
A desired feature of shRNA library is to have high redundancy in number 
of clones per gene, which is important in order to reduce false positive 
results that are due to off-target effects (24, 52).  
Brummelkamp et al. (53) introduced the idea of using vector encoded 
shRNA template sequence as a molecular tag or barcodes to quantitatively 
estimate the abundance of each shRNA vector in the population of cells 
transduced with a library of shRNA expression vectors. The relative 
abundance of each barcode sequence can be quantified by PCR 
amplification coupled with microarray hybridization or next generation 
sequencing (54). Genome-wide shRNA screens (Figure 2) have been 
routinely applied to study gene dependency profile of cancer cell lines and 
identify potential drug targets for cancer treatment (21, 22, 55-57). 
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Figure 2: Genome-wide shRNA screen workflow. A pooled genome-wide shRNA screen 
involves a library construction of pooled plasmids from bacterial culture, followed by viral 
packaging of the shRNA clones, which is done by transfecting large number of packaging 
cells together with packaging plasmids. Virus titres produced after 48-72 hours post 
transfection is pooled and then cell lines of interest for loss-of-function screen are infected 
and selected to eliminate the uninfected ones. Typically, after this step, an aliquot of the 
cells is separated and genomic DNA is isolated and used for a quantification of the initial 
shRNA abundance; and then depending on the experimental design, the cell cultures are 
divided into two or more sets. For instance, in a drug response modifier screen, cells are 
divided into treated and untreated aliquots. Alternatively, in a cell viability screen, a 
sample of cells can be taken and stored for analysis at each passage, to generate a 
viability time-course. The abundance of each shRNA vector at the final time points is then 
measured and compared to the initial conditions to get a quantitative estimate of the 
effect of each shRNAs knockdown on the proliferative capacity of cells (54). 
2.4 Off-target effects in RNAi screens 
One of the pitfalls of RNAi screening technique has been its propensity to 
cause off-target effects; therefore limiting its promise and potential (38, 
45, 58). Transcriptional profiling after inhibition with multiple siRNAs 
targeting the same genes revealed that the siRNAs also produce strong 
downregulation of genes other than their primary targets, and moreover 
each individual siRNA produced a unique fingerprint of transcriptional 
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changes of multiple targets (59). Sequence analysis has revealed that 5’ 
end of the guide strand of the siRNAs may have partial complementarity 
to off-target transcripts, suggesting a sequence-dependent off-target 
effects (60). Biochemical studies also confirmed that 5’ end of the guide 
strand contributes maximally to the target binding and its subsequent 
cleavage (61). Sequence alignment studies revealed that the ‘seed’ region, 
which stretches from 2-8 nucleotide positions at the 5’ end of the 
antisense or guide strand of the siRNA, was enriched in the 3’ UTR region 
of the off-targeted transcripts, suggesting a microRNA-like gene silencing 
pattern (62, 63). Alterations in the seed-region of a siRNA or shRNA may 
also alter the profile of off-targeted transcripts, indicating the importance 
of its role in mediating the off-target effects (63). Likewise, Anderson et 
al. found that siRNAs that have higher number of seed matches to 3’ UTR 
in the transcriptome have a higher propensity towards off-target effects, 
based on the induced gene expression changes (64). 
Silencing of off-target genes mainly arises due to the similarity of the 
siRNA pathway with the endogenous microRNA (miRNA) pathway (58). 
The externally introduced siRNAs utilize and recruit the same components 
of the downstream RNAi machinery to repress the targets, which is also 
utilized for normal gene regulation by the miRNAs (58). Once the guide 
strand of siRNA is loaded into the RISC complex and bound to the target, 
the Argonaute protein of RISC cleaves the target mRNA. Argonaute 
requires perfect sequence complementarity with the target site to induce 
cleavage; hence siRNAs can strongly reduce gene expression. In contrast, 
in the miRNA pathway, complete sequence complementarity of miRNAs 
with target mRNA is not necessary, and the RISC does not induce target 
mRNA cleavage (65). Thus, miRNA induced gene-silencing leads to 
translational repression and is incomplete as compared to siRNA induced 
gene silencing. The partial sequence complementarity in the miRNA 
pathway is mediated by the seed region, extending from 2-8 nt of the 5’ 
end of the guide strand of the microRNA (65). Because of this partial 
sequence similarity requirement, microRNAs are known to have larger 
number of target sites that are generally located in the 3’ UTR regions of 
transcripts, and it is estimated that each miRNA may have potentially ~300 
target sites (66). In addition to target site abundance, other properties 
such as strength of seed pairing at the target site, its location and spacing 
in the 3’ UTR, local sequence and structural context, are other 
determinants of miRNA targeting efficiency (67). Given the similarity 
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between the miRNA pathway and siRNA pathway, these determinants are 
also likely to influence the off-target propensity of siRNAs. 
Off-target effects have also challenged the interpretability of high-
throughput RNAi screens (68), with several studies reporting the top hits 
being false positives. For instance, in a screen designed to identify 
regulators of HIF1-α transcription pathway, the top siRNAs targeting other 
genes were still shown to downregulate HIF-1α by an off-target effect 
mediated through the seed region (60). Similarly, in a screen designed to 
identify modulators of resistance to apoptotic inhibitor ABT-737, the top 
hits were shown to downregulate another key anti-apoptotic protein, 
MCL-1, through seed mediated off-target effects (69). Sigoillot et al. also 
observed nonspecific targeting of MAD2 by the active siRNAs in a screen 
for genes required in spindle assembly checkpoint formation (70). These 
observations highlighted caution in interpreting results from large-scale 
RNAi screens, and also incited alternate strategies to mitigate the false 
positive hits (38, 58). Using multiple siRNAs per gene, appropriate 
controls, internal validation with alternative techniques, and performing 
rescue experiments by expressing a functional version of the target gene, 
are some of the ways to counter off-target effects in RNAi screens. The 
false discovery rates in RNAi screens have been discussed extensively (38). 
Meta-analysis of three genome-scale siRNA screens studying host-factors 
necessary for HIV replication identified virtually no common hits, with <7% 
overlap between any two screens (71). Some studies have also shown that 
the top hits from a genome-wide shRNA screen for synthetic lethal 
partners of the oncogene KRAS was not found to be essential in KRAS 
dependent cancer cell lines, and also did not show any response towards 
its targeted inhibition (72-74). Although the low rate of validation of hits 
can be due to several factors, such as differences in library, experimental 
protocols or screened cell lines, and functional redundancy of genes, 
these observations have raised concerns about the usefulness of large-
scale RNAi screens and the reliability of the findings (39, 75, 76). 
2.5 Methods for inferring gene dependencies from RNAi 
screens 
Genome-scale RNAi screens are experimental techniques that generate 
massive amount of data, and simultaneously create new challenges for 
statistical analyses and interpretation to extract meaningful information 
(77). Statistical handling and analysis of RNAi screening data can 
contribute substantially to the identification of true hits that can influence 
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the consistency and reproducibility of these methods (77). The primary 
goal of a genome-wide RNAi screen is to provide a quantitative estimate 
of the phenotypic effect specific to each gene in a given cellular context. 
Computational methods that can take into the account the library design, 
controls and off-target effects, offer the potential to provide accurate 
estimates of the gene-specific phenotypes. Several computational 
methods for estimation of gene dependency scores have been developed, 
ranging from simple statistical techniques to more sophisticated models 
incorporating seed-mediated off-target effects of the shRNAs (described 
below). 
2.5.1 Redundant siRNA activity (RSA) 
The Redundant siRNA Activity (RSA) analysis method (78) makes use of the 
redundancies in the number of RNAi reagents tested per gene in genome-
scale screens to estimate the probability of a gene being a hit. Simply put, 
the RSA ranks the shRNAs according to their observed quantitative effect 
and calculates an enrichment p-value based on an iterative 
hypergeometric distribution method (79), similar to pathway analyses 
based on Fisher’s exact text. The p-value indicates the probability of the 
shRNAs for the gene being distributed towards the top ranks more likely 
than expected by chance. Because RSA uses probablistic models to infer 
gene-level phenotypes, it is a powerful approach and outperforms the 
cutoff based approach of hit calling based on activity of shRNA scores.  
2.5.2 RNAi Gene Set Enrichment (RIGER) 
RIGER is a non-parametric method (80), which shares similarities with the 
Gene Set Enrichment Analysis (GSEA) technique (81) used in differential 
expression pathway analysis. RIGER utilizes the power of multiple shRNAs 
per screen to estimate whether they are randomly distributed towards 
the top or the bottom of the hit list. RIGER calculates gene-level 
enrichment scores by ranking the entire list of shRNAs, and calculates a 
running-sum test statistic similar to using a Kolmogorov-Smirnov statistic. 
Normalized gene-level enrichment scores are then calculated, which takes 
into account the variability of the number of shRNAs per each gene. The 
RIGER method does not require any arbitrary threshold to estimate the 
enrichment scores. Directional RIGER (dRIGER) (82), an extension of 
RIGER, has also been used for transforming shRNA-level scores into gene-
level scores by computing directional normalized enrichment scores 
(dNES).  
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2.5.3 Gene Activity Rank Profile (GARP) 
GARP score (83) takes into account the dropout behaviour of the shRNAs 
across several time points. First, a summarized shRNA activity ranking 
profile (shRNA) score is calculated by averaging the relative change in 
shRNA abundances, which is normalized by the number of population 
doublings in the assay. Then, from the multiple sets of shRNAs targeting 
the same gene, the average of two shRNAs with lowest shARP scores is 
considered as the GARP score. Statistical p-values are calculated from 
permutation testing across 1000 random scores, as a measure of the 
statistical ‘significance’ of an observed GARP score. 
2.5.4 Analytic Technique for Assessment of RNAi by Similarity (ATARiS) 
ATARiS (84) evaluates the quantitative behaviour of shRNAs targeting the 
same gene across various samples to identify the shRNAs that are likely to 
produce on-target effects. For identifying the on-target shRNAs, ATARiS 
creates a consensus profile from the activity profiles of all the shRNAs 
against a gene in several samples by using information divergence and 
alternative minimization techniques, which separates the shRNA-specific 
effects from the consensus effect. Then, the algorithm performs iterative 
correlation analysis of each of the shRNAs with the consensus profile, and 
discards the ones that are statistically insignificant and recomputes the 
consensus profile. The final consensus profile based on the on-target 
shRNAs is used as the gene-level score. Further, the algorithm also 
calculates a consistency score for each shRNA reagent, indicating the 
likelihood of its on-target effect. Because ATARiS considers the 
consistency of shRNA effects across several samples, the number of 
samples used in the analysis also influence the number of genes for which 
the final scores are derived. 
2.5.5 Gene-specific phenotype estimator (gespeR) 
gespeR (85) performs a statistical modelling for the estimation of gene 
level scores by taking into account the on-target and off-target activity of 
the shRNAs. gespeR uses elastic net regularization to fit a linear regression 
model on the observed shRNA activities against a shRNA-target gene 
relationship matrix. The shRNA-target gene relationship matrix is obtained 
by using the TargetScan algorithm (67, 86), which quantitatively predicts 
the probability of knockdown of off-target genes for each shRNA based on 
its seed sequence. TargetScan also considers other properties of shRNA 
sequences, such as seed pairing stability, target abundance and 3’ UTR 
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location of target site and local AU context to predict the knockdown 
efficiency of off-target genes. The final regression coefficients derived 
after cross-validation are considered as the gene-level scores. 
2.5.6 DEMETER 
DEMETER (87) assumes that each shRNAs phenotypic effect is a linear 
combination of target gene knockdown effects and seed-specific effects.  
DEMETER takes into account the numbers of shRNAs per each gene in the 
library, and also the numbers of shRNAs with the same seed sequence. 
For each shRNA, it considers two seed sequences positions, 1-7 and 2-8 of 
the guide strand. DEMETER performs deconvolution of the shRNA level 
data into a linear combination of gene and seed-level effects using 
stochastic gradient descent. It also provides a performance metric for 
each shRNA, a measure of the variance explained by gene effect and seed 
effect. It was recently shown that the removal of seed effects from shRNA 
level data led to a substantial improvement in the correlation of shRNAs 
targeting the same gene (36). 
2.6 Functional genomic characteristics of cancer cell lines 
 Large-scale sequencing efforts, such as TCGA and ICGC, have aided 
massively in our understanding of the major genetic alterations in cancer 
genomes, in addition to providing an overview of the genomic landscapes. 
The cancer sequencing studies have catalogued an impressive list of new 
genes, previously unknown to be involved in cancer with some genes 
more frequently mutated than others. While these studies are ongoing 
and identifying more genes associated with cancer, alternative strategies 
are also required to make a sense of the plethora of genetic alterations.  
Loss-of-function screens based on RNAi and CRISPR/Cas9 are suitable 
methods for understanding the functional implications of the cancer-
associated genes, which can lead to a better understanding of the 
dependencies of cancer cells on certain genes or biological processes. 
Several efforts are being carried out to functionally characterize large 
collections of cancer cell lines with genome-wide loss-of-function screens, 
along with characterizing their genomic features including mutations, 
copy number variations, transcriptome, proteome and the epigenomic 
profiles. Integrated analysis of these datasets can provide valuable 
insights about the biology of cancer, as well as identify biomarkers for 
patient stratification for the right treatment strategy and novel targets for 
targeted anticancer treatment. 
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2.6.1 Cancer cell lines as models for anticancer therapies 
Preclinical models, such as human cancer-derived cell lines, have 
contributed immeasurably to the understanding of the biology of cancer 
(88). The advantages of in vitro cancer cell lines are multifold: they can be 
easily cultured, are renewable, are amenable to high-throughput assays, 
can be easily adapted to sophisticated experimental designs like studying 
drug resistance modulators, or response to combinations of drugs. 
Moreover, linking the molecular and genetic features of cancer cell lines 
with their phenotypic and drug sensitivity profiles has the potential to 
identify promising biomarkers for targeted therapy (89). The National 
Cancer Institute (NCI) resource (NCI-60), that characterized a panel of 60 
cancer cell line models representing 9 different cancer types was the first 
cell line resource initially setup to screen the activity of a large library of 
compounds (89-91). Initial studies revealed that drugs with similar drug 
response profiles were similar in their mechanism of action, suggesting 
that cellular state influences the phenotypic responses (92). More 
importantly, studies of drug response profiles in NCI-60 panel led to the 
identification of the proteasomal inhibitor, bortezomib, for treatment of 
patients with multiple myeloma, hence highlighting the usefulness of the 
cell line based functional screens (93, 94). Later, it was also found that 
gene expression features are correlated with drug responses, suggesting 
that molecular features of cell lines can be used to predict their functional 
phenotypes (95).  
Genomic characterizations of NCI-60 and other cancer cell line panels 
have revealed that they retain the recurrent genetic and epigenetic 
alterations present in tumors (92). Moreover, cancer cell line models also 
mimic their sensitivity to targeted drugs, for example, lung cancer cell 
lines with oncogenic driver alterations, such as EGFR, BRAF mutations, ALK 
translocations and HER2 amplifications, retain their sensitivity to the 
respective kinase inhibitors, suggesting that they also able to recapitulate 
the therapeutic response profile of tumors (88, 96, 97). However, 
contradicting observations have been made for the comparisons at the 
transcriptome level (98). Lukk et al. performed a combined analysis of 
gene expression data of cancer cell lines and patient tumors representing 
similar tissue types, and observed that the cancer cell lines clustered 
together with each other rather than with the tumor samples of the 
respective tissue type (99). In contrast, Ross et al. observed that breast 
cancer cell lines were able to faithfully recapitulate the tumor subtypes 
based on the gene expression data (100). Additionally, Barretina et al. 
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demonstrated that huge compendiums of cancer cell lines mirrored the 
architecture of human tumors suggesting that profiling a larger panel of 
cancer cell lines would be required to recapitulate the heterogeneity 
present in patient tumors (27). Based on the genomic studies on patient 
tumors by TCGA and other consortia, it was realized that more cell lines 
need to be profiled to capture the genetic variability (36, 89). Hence, 
several projects have been undertaken to molecularly and functionally 
characterize larger panels of cancer cell line models to recapitulate the 
heterogeneity associated with patient tumors (27-29, 33, 35-37, 101-103). 
The use of cancer cell lines for drug discovery efforts have also been 
questioned (104). As they are grown in vitro on plastic surfaces, they do 
not recapitulate the tumor microenvironment and the drug 
pharmacokinetics. Moreover, it has been observed that the adaptation of 
cells to the plastic surface introduces new mutations and genetic 
aberrations that might change their genetic characteristics (105-107).  
2.6.2 Genomic profiling of cancer cell lines 
To model the genetic diversity of tumors, several large scale, pan-cancer 
efforts such as the Cancer Cell Line Encyclopedia (CCLE) (27), Cancer 
Genome Project (CGP), and its resource called Genomics of Drug 
sensitivity in cancer (GDSC) (28, 29, 108), and Genentech Resource (109) 
have recently been undertaken to molecularly characterize panels of cell 
lines from various tumor types. Tissue-type specific panels such as breast 
(110), ovarian (90), non-small lung cancer, head and neck cancer (111) and 
colorectal cancer (112) cell lines have also been profiled separately. 
Comparison of copy number variations (CNV) and gene expression profiles 
of breast cancer cell lines with tumors established that the functionally 
important alterations were preserved, with 72% agreement of the gene 
expression changes (110). Interestingly, a greater number of CNVs were 
observed in the breast cell lines underscoring the caution in clinical 
interpretability of observations from cell lines (110).  
Cancer cell lines from several solid tumor types, including ovarian, head 
and neck and colorectal cancer, closely resemble the mutational profiles 
of their respective tumors, but have higher number of point mutations 
(111-113). Whereas the CNV profiles of head and neck cancer cell lines 
were different from the tumor samples (111), good agreement of the CNV 
profiles of colorectal (112), melanoma (114), non-small cell lung cancer 
(115) was observed. A large panel of cell lines characterized by CCLE, 
approximately 1,000 cell lines representing 36 cancer types, also showed 
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strong correlation of all three genomic profiles: mutation, CNVs and gene 
expression with their respective tumor types in most cases (27). In the 
same vein, the GDSC project, which profiled ~1000 cell lines representing 
29 tumor types, also revealed good agreement in the mutational 
landscapes (28). The GDSC study observed high levels of agreement 
between functional events that were defined as clinically relevant, with 
1063 present in cancer cell lines out of 1273 events present in tumors (28). 
In addition, the authors also reported high agreement for pathway level 
alterations and global signatures of events associated with driver 
mutations.  
Transcriptomic analysis of 675 cancer cell lines comprising of 18 tissue 
types from the Genentech resource revealed that the lymphoid cell lines 
clustered separately from the set of cell lines or other tissue types as 
observed in previous studies (99, 109). Moreover, the latter group further 
sub-clustered into epithelial and mesenchymal subtypes correlating with 
the classification based on genes associated with epithelial-to-
mesenchymal transition (EMT)-signature (116). Although EMT is a 
transdifferentiation program activated in cells during embryonic 
development (117, 118), its induction has also been correlated with 
invasive and metastatic potential of cancer cells during tumor progression 
(116, 119-123), and more importantly with the emergence of drug 
resistance (124-126). Importantly, the acquisition of mesenchymal traits 
through EMT is associated with the expression of stem cell markers, i.e. a 
cancer stem cell (CSC)-like phenotype (119, 127). CSCs are known to self-
renew and contribute to tumor heterogeneity and are resistant to chemo- 
and radiation therapy (126, 128-130). Several studies have identified 
subpopulations of CSC-like cells in cancer cell lines from breast (131-134), 
glioma (135) and head and neck cancer (136), demonstrating that cancer 
cell lines can also be used to study the survival mechanisms of CSCs.  
2.6.3 Functional profiling of cancer cell lines 
Lessons from genomic studies of cancer cell lines have fortified their use 
as faithful models for expediting the discovery of effective targets for 
precision anticancer treatment. However, these studies do not provide 
answers on whether the identified genomic alterations are important for 
the tumor biology, and whether they yield a therapeutic opportunity as 
druggable targets. Hence, several large-scale efforts based on loss-of-
function and drug sensitivity screens have also been undertaken to 
functionally characterize the cancer cell line panels. Project Achilles (32, 
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36, 102), by the Broad Institute, performed systematic genome-wide RNAi 
screen of 501 cancer cell lines, representing 30 different cancer types and 
identified ~750 genes that are differential essential in cancer cell lines 
(36). The authors observed that only 76 genes from this set was present 
in almost 90% of the cell lines, suggesting that the same essential genes 
are relevant across many tumors. Moreover, a substantial proportion of 
the essential genes were also druggable (36).  
An earlier report from Project Achilles also revealed essential genes that 
are tissue-specific and aberrantly activated due to amplification or 
overexpression in multiple cancer types (102). The Project DRIVE also 
interrogated the functional effect on cell viability of ~8000 genes by 
genome-wide shRNA library in nearly 400 cancer cell lines, representing 
26 cancer types and identified the dependence of cancer cell lines on 
lineage-specific transcription factors (33). Marcotte et al. observed that 
the gene essentiality profiles of breast cancer cell lines partially 
corresponded to the breast tumor subtypes, in addition to observing 
driver mutation-specific and cancer type-specific dependencies (83). The 
COLT-cancer database comprises of functional profiles from genome-wide 
shRNA screening of ~15000 genes in 72 cancer cell lines from pancreatic, 
ovarian and breast cancer types (37, 83). In another study on a larger 
panel of breast cancer cell lines, Marcotte et al. identified gene 
dependencies in EGFR and MAPK pathway genes that were correlated 
with the response of the cell lines to targeted inhibitors of EGFR/MEK/ERK 
(34). Recently, genome-wide CRISPR/Cas9 based knockout screens have 
also been performed in large panel of cancer cell lines (137-141), revealing 
potential targets for acute myeloid leukemia (139), and vulnerabilities 
important in the context of KRAS mutated cancer cells (137).  
In addition to the functional profiles based on loss-of-function screens, 
several studies have performed drug sensitivity profiling of cell lines 
against a library of small molecules. The CCLE profiled the activity of 24 
targeted and cytotoxic agents against cancer cell lines at several doses, 
and by performing predictive modelling with elastic-net regression, they 
identified several genomic predictors of the drug responses (27). Similarly, 
the Cancer Therapeutic Response Portal (CTRP) (30, 31) and GDSC (28, 29) 
projects have also profiled the activity of a library of drugs, 480 and 265 
respectively, in a larger panel of cell lines. Drug sensitivity screens have 
also been used to identify CSC-specific inhibitors in breast epithelial cell 
lines induced to undergo EMT (142). Although drug sensitivity screening is 
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not a functional genomics tool in its true sense, it provides 
complementary information on the phenotypic characteristics of the cell 
lines, and has led to identification of novel drugs for cancer treatment (26, 
143, 144). However, drug screens also suffer from the off-target effects 
and promiscuity of inhibitors to modulate related proteins, making it 
difficult to attribute the observed drug responses to their primary targets, 
also called target deconvolution problem of phenotype-based drug 
discovery approach.  
2.6.4 Consistency of functional and genomic datasets 
With the availability of genomic and functional profiles of cancer cell lines 
from different laboratories, a natural question that arises is how 
consistent these profiles are. Cancer cell lines are known to acquire 
genetic aberrations during the culturing process, and because cancer cell 
lines are widely used across research labs, it is important to understand 
whether the datasets generated from the panels of cell lines by various 
studies draw a consistent portrait. In addition, the consistency of the 
datasets can also be influenced by laboratory protocols and workflow, 
experimental factors such as cell confluency, genomic drift, clonal 
variations, growth medium, the robustness of the platform being used for 
high-throughput measurement and computational methods used in data 
post-processing (145).  
Genomic platforms are known to be quite robust and extensive work has 
gone into standardizing workflows and data processing pipelines. 
Encouragingly, comparison of the transcriptomes of cell lines profiled 
commonly in the Genentech Resource with CCLE and CGP have revealed 
nearly 80% agreement between the datasets (109). Comparison of gene 
expression and mutational profiles between CCLE and CGP also indicated 
high correlation levels (109). In contrast, the consistency of drug 
sensitivity screens has been a matter of recent debate with several groups 
reporting dissimilar observations (40, 146-148). Originally, Haibe-Kains et 
al. observed only ~30% agreement between drug responses measured in 
CCLE and CGP (40). In subsequent analysis, Mpindi et al. observed that 
correlation of the profiles could be increased up to 70% by using 
standardized metrics of quantifying drug sensitivity, and by standardizing 
assay methods and protocols (148). It was also observed that higher 
concordance can be achieved by using more biologically motivated 
statistical analysis methods, and accounting for experimental factors like 
cell seed density and cell growth media (149). Functional profiles based 
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on genome-wide RNAi screens are also known to be noisy and 
inconsistent, mainly due the off-target effects mediated by partial 
complementarity (38, 58). However, systematic comparisons of the 
consistency of RNAi or CRISPR/Cas9 datasets have not been performed. 
2.7 Integrating genomic and functional profiles 
The goal of precision medicine and targeted cancer therapy is to identify 
biomarkers that will help tailor the best treatment option for each patient. 
Treatment of breast cancer patients overexpressing HER2 receptor with 
HER2 antibodies, and leukemia patients harboring BCR-ABL fusions with 
imatinib are some successful examples, based on the idea of oncogenic 
addiction, demonstrating how single genomic markers can guide effective 
cancer treatment (8, 18). However, the genetic alterations in many cancer 
driver genes do not always correspond to it being essential for survival. 
Extensive genetic heterogeneity resulting from multiple alterations also 
makes it difficult to pinpoint the specific dependencies in cancer cells. 
Integrative analysis of molecular features of cancer cell lines and their 
functional profiles can be used to identify the genetic dependencies 
associated with a certain genetic background.  
2.7.1 Beyond oncogene addictions: synthetic lethality  
Synthetic lethality is defined as the significant reduction of cellular 
viability due to simultaneous loss-of-function of two partner genes, such 
that when the genes are inhibited individually they do not compromise 
the cell viability (150-153). Cellular signalling is a robust process with 
several feedback loops and functional redundancies which ensure that 
cells are capable of surviving when a certain genes’ function is lost or 
inhibited (151). Thus, simultaneously inhibiting these functionally 
redundant genes to compromise the viability of cancer cells is a promising 
strategy for anticancer treatment (152, 153). The idea is to exploit on the 
vulnerability of cancer cells; having a frequently occurring genomic 
alteration makes the cancer cells more dependent on the synthetic lethal 
partner for survival. It is expected that only cancer cells harbouring the 
genetic alteration will be sensitive towards the inhibition of the activity of 
the synthetic lethal partner gene, hence having a broader therapeutic 
window and less side effects in normal cells (154). Moreover, targeting 
synthetic lethal partner of tumor suppressors, which already have loss-of-
function mutations, is especially beneficial as they are not easily amenable 
to drug inhibition (154). The synthetic lethality approach is different from 
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the concept of ‘oncogene addiction’ which is based on inhibiting the 
activity of single altered driver oncogene, such as HER2, BCR-ABL, EGFR 
and BRAF (154).  
Synthetic lethality provides also a framework for associating the genomic 
features of cancer cells with their phenotypic characteristics. Functional 
profiles from genome-wide loss-of-function screens in cancer cell lines are 
a rich source of information for identifying novel synthetic lethal 
interactions and have been used routinely in the past (22, 155). Frequently 
occurring genetic alterations of cancer driver genes are associated with 
changes in the cellular signalling and processes, which renders the cancer 
cells being vulnerable to their inhibition. For instance, mutations in the 
BRCA1 and BRCA2  genes are associated with sensitivity of the cancer cells 
towards inhibition of DNA repair machinery (156-158). BRCA genes are 
involved in repair of DNA breaks by homologous recombination, and thus 
the inhibition of PARP genes that are involved in base excision repair 
results in a strong synthetic lethal interaction with BRCA. Several 
synthetic lethal screens in cancer cell lines have identified putative 
synthetic lethal partners of undruggable cancer driver genes, such as 
KRAS, MYC and TP53 (159). Genome-wide RNAi screens in panels of 
mutant KRAS and wild-type cell lines or isogenic cell line pairs identified 
several synthetic lethal partners such as PLK1, SKT33 (160).  
However, it has been difficult to translate these findings to a clinical 
setting due to lack of supporting evidence in other cell lines, in vivo 
models or by drug targeting. So far, only one anticancer treatment 
based on the synthetic lethal strategy has progressed to the clinical 
practices, namely, the approval of PARP inhibitors for treatment of 
breast cancer patients with germline BRCA mutations (159). One reason 
for such disappointing clinical translation rate is that robust synthetic 
lethal interactions are difficult to identify, as they are known to be 
highly context-dependent and influenced by the genetic background or 
microenvironment of the tumors (161). Moreover, genome-wide RNAi 
screens are known to be noisy and contain wide off-target effects, which 
further make it harder to detect the true synthetic lethal hits from the 
background noise. It has been argued that integrated analyses to 
identify robust, context-specific synthetic lethal interactions  a panel of 
cell lines from a variety of lineage backgrounds and various genomic and 
functional datasets may lead to the identification of clinically actionable 
synthetic lethal partners of cancer driver genes (162). 
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Figure 3: Concept of synthetic lethality for cancer treatment. While normal cells have 
functional protein products of both gene A and gene B, cancer cells may have loss-of-
function mutations in either gene A or gene B individually and are are still viable. 
However, loss-of-function of both genes in the same cell either by mutation or knockdown 
or pharmacological inhibition results in synthetic lethality. Modified from O’Nell et al. 
(161). 
 
2.7.2 Machine learning models for predicting functional profiles in cancer 
cells  
In recent years, the application of machine learning methods in the field 
of genetics and genomics has tremendously increased and also proved to 
be very useful (163). For instance, machine learning can be used to 
identify the location of  transcription start sites, promoters, splice sites or 
enhancer sites in the genome (163). Artificial intelligence is another field 
of computer science that deals with the science of making machines that 
are able to perform intelligent and rational tasks, akin to thinking like 
humans; machine learning on the other hand is a way of achieving artificial 
intelligence (164). Machine learning involves the building and application 
of algorithms with the ability to ‘learn’ i.e. become better at a given task 
with experience. It is therefore a data-oriented field geared towards 
problems for which data is available, and on which we can learn and get 
better at prediction. Machine learning methods can be principally 
categorized into: supervised learning or unsupervised learning. 
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Supervised learning requires the use of  labels or known examples to 
train  the algorithm, which is then used to predict the respective labels 
of unlabelled cases. In contrast, unsupervised learning is concerned 
with finding patterns or clusters in unlabelled data sets, i.e. without any 
prior knowldege (163).   
The availability of large-scale functional screening profiles of cancer cell 
lines that are also molecularly characterized allows the possibility to build 
computational models that can capable of predicting the phenotypic 
responses and also identify the relevant genomic biomarkers. Building 
predictive computational models is a challenging task because of reasons 
such as: molecular heterogeneity of cancer types, data complexity in 
terms of size, noise, and standardization and normalization of datasets 
from multiple sources. However, machine learning algorithms are well-
suited for building predictive models (165). Several machine learning 
models, such as support vector machines, elastic net regression, neural 
networks and random forest, are commonly used to solve such problems 
(163).  
The core idea is straightforward: given the genomic features of cell lines 
and their functional profiles as input, the task is to learn a model that can 
predict the gene dependencies or drug responses in unseen cell lines or 
tumor samples. The standard strategy for developing such supervised 
machine learning models is as follows: first obtain the relevant normalized 
datasets containing the molecular features that is used as features, and 
the functional profiles which is considered as the predictor variable. In the 
second step, the predictive model is trained and selected using the input 
data using several statistical and machine learning frameworks. The model 
choice is dependent on the characteristics of the input and output 
datasets. While nonlinear models can capture complex interections 
between the input features in the dataset, linear models are easier to 
interpet, scalable and therefore more preferred (166). Thirdly, the trained 
model is tested on independent datasets to verify the predictive accuracy 
of the model (165).  
Supervised machine learning tasks can be categorized into regression and 
classification problems. In regression models the data to be predicted is a 
continuous variable, whereas the later deals with variables that are 
categorical in nature, such as, high response vs. low response. In 
regression models, the functional profile which is to be predicted can be 
modelled as a linear combination of the predictor variables.  
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 ! = # + 	Χ' + ( 
 
Where y is a vector of the observed functional profile to be predicted, μ is 
the intercept, C is a matrix of the molecular features, such an gene 
expression and copy number varation, and b is the regression coefficient 
and e is the vector of residual errors.  
Regularized regression models are often used to control model 
complexity, to avoid overfitting of the training data and enable the 
generalizability to unseen data. Regularization approaches introduce 
penalty terms such as L1 and L2 norms for regression coefficients. Ridge 
regression solves the problem using L2 penalized least squares and is 
suitable in cases when there are many predictors with small effects. It is 
formulated as  
 ')(+,-.() = argmin6 ‖! − 9'‖:: +	;‖'‖:: 
where, 
 ‖!	 − 9'‖:: 	= 			< (! − =>?'):@>AB  
 
is the residual sum of squares loss function, and =>? is the i-th row of X,  ‖'‖:: = < 'C:DCAB  
 
is the L2 norm penalty, and ;	 ≥ 0 is the tuning parameter, also known as 
the regularization parameter. The regularization parameter is used to 
shrink the variable coefficents towards zero to prevent any particular 
variable from having too large effect on the model. In contrast, lasso uses 
the L1 norm penalty to build sparse models with few non-zero 
coefficients, and hence suitable for feature selection.  
 '	G (HIJJK) = argmin6 ‖! − 9'‖:: +	;‖'‖B 
where,  
 ‖'‖B = < L'CLDCAB  
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is the L1 norm penalty used for introducing sparsity in the solution, with ;	 ≥ 0. Elastic net regression uses a mixture of the L1 and L2 penalties and 
can be thought of as an extension of lasso, but with the property to select 
variables that are still highly correlated.  
 '	G ((HIJM,N	O(M) = Pargmin6 ‖! − 9'‖:: + ;:‖'‖:: +	;B‖'‖BQ 
 
Systematic analyses of various modelling approaches by Jang et. al. 
previously showed that the predictive accuracy is determined largely by 
the type of molecular data used as input and the choice of learning 
algorithm (167). They found that elastic net and ridge regression models 
applied to continuous response variables, such as drug response, were the 
best predictors. Moreover, modelling choices are also dependent on their 
ability to utlize multiple datatypes. For example, gene expression data is a 
continuous type of input data, whereas copy number variation data and 
mutation data can be categorical. A commonly used model building 
strategy is to combine all the input molecular features and train a single 
model. Other strategies of multiview learning based on multiple kernels 
have also been applied (168, 169).  
Machine learning algorithms based on linear models have been generally 
well formulated theoretically. However, real world problems involve 
complex relationships between variables that are often not captured by 
the linear modelling assumptions. Non-linear modelling approaches can 
be better in detecting these dependencies. To model the non-linear 
relationships, kernel methods  have been used regularly over the past few 
years. Kernel methods map the data into higher dimensional space using 
a kernel function such that the data becomes well structured and 
separated. Essentially, a kernel is a dot product between two feature 
vectors which is also used as a similarity measure. The advantage with 
using kernel functions is that when the input data is mapped into a higher-
dimensinal space, a linear dependency that exists in this space will behave 
non-linearly in the original input space. (170) Non-linear models have also 
been used previously to predict drug sensivities in cancer cell lines (169). 
The top performing model in the NCI-DREAM Challenge, which compared 
the performance of machine learning models for predicting drug 
responses in breast cancer cell lines among several teams, was based on 
kernelized regression. The winning algorithm, known as Bayesian 
multitask multiple kernel learning (MKL) method leveraged four 
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machine-learning principles: kernelized regression, multiview learning, 
multitask learning, and Bayesian inference. The kernelized regression 
approach computes kernels, similar to support vector machines, 
between the cell lines which reduces the number of model parameters 
and also captures the non-linear relationships between the molecular 
features.  
Several studies have developed predictive machine learning models of 
drug response in the CCLE and GDSC dataset, using molecular and 
genomic information available from gene expression, CNV and mutation 
data (27-29, 171-175). The NCI-DREAM Challenge found that the best 
performing machine learning model integrated information from various 
datatypes, such as genomic, proteomic and epigenomic profiles (169). The 
study also observed that gene expression data was the most predictive 
compared to all other data types (169). Likewise, Kim et al. developed a 
computational method based on mutual information metric to identify 
combinations of mutually exclusive genomic features that are associated 
with the gene dependency profiles as well as drug response profiles (176). 
These in silico prediction tools have been used to predict drug responses 
in cancer cells, and can potentially help the prioritization of promising 
drugs and targets for further research and clinical validation leading to 
significant reduction in experimental costs. 
However, a key challenge in building predictive machine learning models 
is the high dimensionality of genomic datasets and the low sample sizes, 
also called as the ‘small n, large p’ problem (177). This often leads to low 
power and makes robust inference problematic, and consequently the 
clinical translatability of these models is often limited. Also, the predictive 
models are built on a simplistic paradigm: learning a regression model 
between the predictors and outputs. With the availability of multiple data 
sources, it is advantageous to model the shared relationships between the 
variables to increase the predictive performance, using so-called multi-
task learning approaches. Another shortcoming of the existing modelling 
approaches is that they are heavily dependent on ‘statistical’ treatment of 
the data. Thus, there is a need to integrate the several layers of biological 
information in a systems modelling framework that takes into account the 
dynamic cross-talk and network properties of genes (178). 
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3 Aims of the study 
The primary aim of this thesis is to develop and apply novel computational 
methods to integrate the functional and genomic characteristics of cancer 
cell lines. The goal is to identify promising drug candidates and predictive 
biomarkers for targeted anticancer treatment strategies. The specific aims 
can be summarized as follows: 
1. Develop and assess computational approaches to increase 
reproducibility of gene dependencies identified in cancer cell lines 
based on genome-wide RNAi screens.  
2. Predict novel synthetic lethal interactions in cancer cell lines based on 
normalized RNAi screening datasets, sub-sequently confirmed with 
CRISPR/Cas9 assays. 
3. Develop computational approaches for predicting gene dependencies 
in cancer cell lines based on their integrated genomic and molecular 
profiles. 
4. Predict drug response of cancer cell lines to cancer stem cell inhibitors 
using novel transcriptional signatures. 
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4 Materials and Methods 
In this section, I will briefly describe the data sets used in this thesis, along 
with experimental procedures and cell lines, and the computational 
models and statistical analysis that were applied in the studies. A detailed 
description of the materials and methods can be found in the original 
publications (I-III). 
4.1 Datasets  
 
Publication Data set Data type Material 
Number of 
samples 
I 
Project Achilles 
2.0 (102) 
shRNA screen Cell lines 102 
I, II 
Project Achilles 
2.4 (32) 
shRNA screen Cell lines 215 
I 
COLT-Cancer 
(83)  
shRNA screen Cell lines 72 
I BFG (34) shRNA screen Cell lines 77 
I, II CCLE (27) Mutation Cell lines 1074 
II, III CCLE Expression Cell lines 1074 
II CCLE CNV Cell lines 1074 
III TCGA (179) Expression 
Patient 
tumors 
8226 
III ESTOOLs (180) Expression 
Embryonic 
stem cells 
and 
fibroblasts 
653 
 
Table 1: Data sets and datatypes used in each publication included in the thesis.  
4.2 Cell lines for profiling experiments 
MCF10A cell line harboring PIK3CA mutations and its corresponding 
wildtype isogenic controls were purchased from Horizon Discovery Group 
(city, country) for publication I. These cell lines along with 293 packaging 
cell line for lentiviral packaging was used for CRISPR/Cas9 knockout 
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screening. 15 cancer cell lines used for drug sensitivity testing in 
publication III were profiled by GenScript profiling services (Finland). 
4.3 CRISPR/Cas9 knockout assay 
For publication I, single guide RNAs (sgRNAs) against target genes were 
obtained from SigmaAldrich (Helsinki, Finland) and lentiviral particles 
were generated by transfection using lentiviral plasmids and packaging 
plasmids. Cas9 expression cell lines were generated and transfected with 
lentivirus particles packaged with the sgRNAs. 
4.4 Statistical analysis 
Rank-based Spearman correlation was used for assessing the concordance 
of essentiality phenotypes (publication I), for evaluating the agreement 
between predicted and observed gene essentiality scores (publication II), 
and for identifying co-expressed genes (publication III). Paired t-test and 
Wilcoxon rank sum tests were used for comparing normal and non-normal 
distributions, respectively, in publication I. Permutation-based statistical 
testing was carried out in publications I and II to assess the statistical 
significance of different types of observed quantities. The advantage of 
permutation tests is that it does not require any distributional 
assumptions, and hence useful when the actual distribution is unknown, 
or when the sample sizes are not large enough for large-sample 
assumption. 
4.5 Survival analysis 
TCGA datasets obtained from cancer patients also contain clinical 
information related to patient survival. Survival analysis related to given a 
biomarker or gene signature is a useful method for assessing its clinical 
relevance, in which a comparison of survival time is done between two 
patient groups, defined based on the biomarker or signature. Kaplan-
Meier survival analysis was performed in publications II and III to assess 
the effect of the identified gene expression signatures on patient survival 
in TCGA datasets. 
4.6 Clustering analysis 
Unsupervised hierarchical clustering was used in publication III for 
assessing the gene expression signature pattern in ESCs and fibroblasts, 
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and cancer cell lines. Clustering methods are useful in resolving patterns 
and identifying sub-groups in a complex dataset, and routinely used in 
analysing gene expression profling data. There are several agglomerative 
clustering approaches, in which the clustering process starts from the 
bottom. Specifically, each gene or sample is first considered as a singleton 
cluster, and sub-sequentially these clusters are merged together to form 
larger clusters, and eventually the entire dataset is part of a big cluster. 
The sequence of merging each node into larger clusters can be 
represented as a dendrogram. 
4.7 Machine-learning models 
In publication II, the Multi-Target Greedy Regularized Least-Squares (MT-
GRLS) algorithm based on linear modelling was used. MT-GRLS constructs 
a multi-target ridge regression models given a budget restriction on the 
number of common features to be selected for performing the multiple 
tasks i.e. gene essentiality predictions (181, 182). For selecting the 
genomic features, MT-GRLS performs step-wise greedy forward selection, 
starting with an empty feature set, and then in each iteration adds the 
feature whose addition results in the maximal accuracy gain, e.g, 
minimum sum of squared error in the leave-one-out cross-validation 
(LOO-CV). MT-GRLS optimizes the predictive performance subject to an 
explicit joint budget constraint on the number of features. The advantage 
of MT-GRLS algorithm is that it performs the feature selection 
computationally much more efficiently compared with a straightforward 
wrapper type of implementation. In a dataset with d features and m 
training samples, the time complexity of a standard wrapper approach 
using LOO-CV for forward selection of k common features for 
simultaneous prediction of t tasks with RLS would be R(S,O{UVS:-M, U:SV-M}). In contrast, the time complexity of MT-GRLS 
is only R(US-M).  
4.8 Broad-DREAM Gene Essentiality Prediction Challenge 
The DREAM Challenges are crowdsourcing challenges examining 
challenging questions in biology and medicine (183). The DREAM 
challenge organizers pre-test all data and predictions, and develop custom 
scoring methodologies to ensure high-quality data and rigorous 
performance evaluation. Such crowdsourcing competitions produce 
standardized data sets and benchmarked methods for future comparison, 
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analysis, and model development (184). Crowdsourcing competitons can 
be a useful approach to doing scientific research. It can reveal a variety of 
approaches towards solving the same task. It can also reveal biases in 
scientific conclusions that are based on subjective analytical approaches. 
Since each pariticipating team contributes to the competition with its own 
findings, a range of results are revealed which can be useful in guiding the 
research towards a fruitful direction (185). 
The goal of the Broad-DREAM Gene Essentiality Prediction Challenge was 
to use a crowd-based competition to develop predictive computational 
models that can infer gene dependencies of cancer cells using their 
molecular and genomic features. Participants were provided with gene 
essentiality datasets generated from genome-scale shRNA screen in a 
panel of cancer cell lines, to be used as response variables. Gene 
expression data, copy number data, and mutation data were provided to 
the participants to be used as predictor variables. A hold out set was used 
to score the prediction performance of each team. There were three 
major tasks defined: 
i. Sub-challenge 1: Build a model that best predicts the gene 
essentiality values of thousands of genes, using the molecular and 
genomic characteristics/features of the cancer cell lines. 
ii. Sub-challenge 2: Identify the most predictive features for each 
gene essentiality among a prioritized list of genes. For each 
prioritized gene, the aim was to select a small set of at most 10 
predictive features (gene expression, copy number, and mutation), 
and then predict gene essentiality using only these features. 
iii. Sub-challenge 3: Identify the most predictive features common for 
all gene essentiality values of a prioritized list of genes. For the set 
of all prioritized genes, the aim was to identify a single list of at 
most 100 shared predictive features, and then predict essentiality 
using only these features for all the prioritized genes. 
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5 Results 
In the following sections, I present the results that highlight my 
contributions to the development of computational approaches and their 
application to advancement of cancer biology in general, and precision 
oncology in particular.  
5.1 Consistency of genome-wide shRNA screens  
To assess the consistency of genome-wide RNAi screens, I made use of the 
publicly available datasets based on genome-wide shRNA screens in large 
panels of cancer cell lines from different research laboratories. Project 
Achilles is an initiative by the Broad institute, wherein 102 cell lines from 
various cancer types were screened in the first phase, Achilles 2.0 (186), 
and later extended to 216 cell lines in Achilles 2.4 (32). COLT-Cancer (187) 
and Breast Functional Genomics (BFG) (34) datasets were generated by 
the Moffat lab and Neele lab respectively at the University of Toronto 
(Canada). 
The Achilles projects used a genome-wide shRNA library of ~54k shRNAs, 
whereas the Toronto projects screened a library of ~78k shRNAs (Figure 
4). However, all screens used the common library obtained from the same 
resource, The RNAi consortium (TRC) database. While Achilles 2.0 and 
COLT-Cancer measured shRNA abundances by microarray hybridization, 
Achilles 2.4 and BFG used NGS for the same. All the screens are similar in 
terms of their experimental workflow for conducting a genome-wide 
shRNA screen, with differences in the number of population doublings 
before the final shRNA abundance measurement. A substantial number of 
identical cell lines were also screened in between the Achilles and Toronto 
projects (Figure 4), making it possible to perform a quantitative 
assessment of the consistency between studies in terms of the shRNA-
level phenotypes and gene-level dependencies in publication I. 
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Figure 4: Overlap in shRNAs and cancer cell lines screened in the Project Achilles, COLT-
Cancer and Breast Functional Genomics (BFG) screens. 
 
 
Figure 5: Heatmap of rank correlation of shRNA essentiality scores (shES) between 
Achilles 2.4 and COLT-Cancer projects for common set of shRNAs and cell lines.  
 
Correlation analysis of shRNA-level phenotypes, i.e. shRNA essentiality 
scores (shES) for the common set of shRNAs between the identically 
screened cell lines in Achilles 2.4 and COLT-Cancer, revealed a moderate 
consistency between the two studies (mean rank correlation = 0.57) 
(Figure 5). Moreover, the between-study correlations between identical 
cell lines was systematically higher than either the intra-study or inter-
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study correlations between the non-identical cell lines, suggesting that 
the phenotypic effects of shRNAs are significantly influenced by the 
genetic background of the screened cell line (Figure 5). In addition, the 
type of platform for measurement of shRNA abundance also influenced 
the consistency of the screens. Average correlation between screens using 
microarray hybridization, Achilles 2.0 and COLT-Cancer was much lower 
(mean rank correlation = 0.38), than between screens using NGS, Achilles 
2.4 and BFG (mean rank correlation = 0.53). 
While a quantitative estimate of the shRNA-level phenotypic effects on 
cell proliferation is the outcome of a genome-wide shRNA screen, 
quantifying the gene-level dependencies of cancer cells is desired for 
analytical purposes and for building predictive computational models. 
Since shRNAs are known to exhibit off-target effects, the methods for 
summarization of shES scores into gene essentiality scores (geneES) can 
influence the accuracy of inferred genetic dependencies of cancer cells, 
and consequently the consistency of genome-wide shRNA screens. 
Methods summarizing the intended on-target activity of shRNAs, such as, 
RIGER, ATARiS, RSA and average gene essentiality (AGE), led to a decrease 
in the consistency of the Achilles 2.4 and COLT-Cancer screens, in 
comparison to the shES-based rank correlation estimates (Figure 6A). In 
contrast, the correlation of GARP-based geneES for identical cell lines did 
not decrease significantly. Surprisingly, the consistency between the two 
screens increased significantly (mean rank correlation = 0.71, 
p = 8.6 × 10−08), when analysed based on seed essentiality (seedES) scores. 
seedES summarizes the off-target activity of shRNAs, by averaging the 
shES of all shRNAs having an identical nucleotide sequence at the seed 
region (position 2-8) of the guide strand.   
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Figure 6: (A) Boxplot of rank correlations between Achilles 2.4 and COLT-Cancer screens 
based on shES, geneES and seedES. Asterisks indicate statistically significant differences 
in correlations (p < 0.05, paired t-test). geneES scores are estimated by RIGER, GARP, AGE 
and ATARiS methods which summarize the intended on-target effect of shRNAs. Average 
Gene Essentiality (AGE)-based geneES were calculated by averaging the shES scores of all 
shRNAs targeting an intended gene. SeedES were calculated by averaging the shES of sets 
of shRNAs having the same seed sequence, with set size >= 5. Hepatmer12-18ES is the 
average shES of shRNAs having identical sequence from positions 12-18. (B) Boxplot of 
rank correlations based on shES for shRNAs categorized based on their biochemical seed 
sequence properties: seed pairing stability (SPS) and target abundance (TA). shRNAs were 
categorized into combinations of strong SPS or weaker SPS, and lower TA or higher TA. 
Asterisks denote statistically significant differences in correlation (p < 0.05, paired t-test). 
 
 
Further, it was found out that properties of seed sequences that are 
known to affect the off-targeting tendency of shRNAs alsoinfluenced the 
consistency of the screening results (Figure 6B). The sequence 
composition of seed region of a shRNA is known to affect its biochemical 
properties, such as how strongly it pairs with off-target mRNAs or many it 
can bind with (86). Seed pairing stability (SPS) is a measure of the 
thermodynamic stability of the seed-mRNA duplex, and target abundance 
(TA) is a measure of the availability of target mRNAs with a seed 
complementary sequence. Stronger SPS values suggest that the binding is 
more stable and hence having a higher likelihood of off-target effects, and 
vice-versa for weaker SPS values. Higher TA values mean more number of 
available target mRNAs and the shRNAs are titrated out, thus having 
milder effect on down-regulation of off-target mRNAs. The consistency of 
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the two screens was remarkably lower for shRNAs categorized as stronger 
SPS and lower TA or stronger SPS and higher TA (Figure 6B).  
5.2 Prediction of novel synthetic lethal interactions 
Genome-wide RNAi screens can be used to identify the context-specific 
addictions of cancer cells, for instance, the addictions that are present in 
the cancer cells having a mutated driver gene while not in the wild type 
background. Such context-specific dependencies, also known as synthetic 
lethal interactions, serve as a useful principle for identifying non-direct 
approaches for targeted therapy. The Achilles 2.4 and COLT-Cancer 
studies have profiled large panels of cell lines from a wide background of 
lineages, which allowed us to perform statistical analyses to detect 
candidate genes that are robust synthetic lethal partners, i.e. differentially 
dependent, of frequently mutated cancer driver genes in publication I.  
Moreover, identification of robust synthetic lethal interactions is also 
dependent on the accuracy of gene dependency estimates and the genetic 
background in which the context-specific dependency relationships exist. 
The accuracy of gene dependency estimates can be improved by 
accounting for the off-target effects of shRNAs. It was found out that 
removing the shRNAs with higher propensity for off-target effects, based 
on their seed sequence properties, from the estimation of GARP-based 
geneES scores led to an improved consistency between the Achilles 2.4 
and COLT-Cancer screen in publication I. Likewise, we observed an 
improvement in the common number of synthetic lethal candidates 
identified between the two screens for several cancer driver genes (Figure 
7). In addition, similar improvement in identification of genetic interaction 
partners of the cancer driver genes was also observed. 
To test whether this approach was successful in predicting novel synthetic 
lethal partners, we further studied the synthetic lethal partner of PIK3CA 
driver oncogene that were identified only post-removal of shRNAs with 
higher propensity of off-target effects. Two putative synthetic lethal 
partners, PKN3 and HMX3, were identified as synthetic lethal hits of 
PIK3CA gene in both of the datasets. Knockout of these genes using 
CRISPR/Cas9 in isogenic MCF10A cell lines having two different PIK3CA 
driver mutations, E545K and H1074R, led to a systematic decrease in 
proliferation of the cells, hence confirming the robust synthetic lethal 
nature of these genes with PIK3CA.  
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Figure 7: Systematic increase in overlap of synthetic lethal candidate partners of several 
cancer driver genes after removing the shRNAs with higher propensity of off-target 
effects. P-value is calculated based on a Wilcoxon signed rank test. 
 
5.3 Predicting gene dependencies in cancer cell lines 
Predicting gene essentiality profiles of cancer cells using genetic and 
molecular profiles can provide biological insights into the systems-level 
genetic interactions and dependencies across cancer cells. The task in the 
Broad-DREAM essentiality prediction challenge (publication II) was to 
build machine learning models that can best predict the gene dependency 
profiles of cancer cells using their genomic and molecular profiles.  
For sub-challenge 2 and 3, in which the task was to predict gene 
essentialities of selected 2467 genes, the MT-GRLS model was 
implemented (Figure 8). MT-GRLS performs step-wise greedy forward 
selection by adding at each step the feature whose addition leads to the 
largest increase in leave-one-out cross-validation performance over all the 
target genes. The algorithm is highly scalable having a linear time training 
complexity, and it directly optimizes the predictive performance of the 
learned model subject to the budget constraints, making it ideal for these 
sub-challenges.  
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Figure 8: Schema for learning the MT-GRLS model for predicting gene dependencies of 
cancer cell lines. Training data for 105 cell lines were used in a nested cross-validation 
setting to select the best model parameters (λ) with maximum predictive performance in 
the training data. The final selected parameter was used in the test data of 44 cell lines. 
 
 
Before applying the MT-GRLS, we implemented data-preprocessing steps 
to reduce the number of redundant and non-informative genetic and 
molecular features. For the genes with identical CNV profile across all the 
cell lines, we used the first non-duplicate row to reduce the number of 
duplicate features (i.e. identical CNV profiles). Missing mutation status 
data  were treated as wild type and the genes with zero-variance in their 
mutation profiles across the cell lines were removed. Finally, all the 
features (i.e. gene expression, CNV and mutation data matrices), as well 
as the gene essentiality profiles (response variables) were normalized to 
zero-mean and unit variance. We evaluated the performance of MT-GRLS 
model internally, using a nested-cross validation (CV) approach (Figure 8). 
First, we applied the model over a range of regularization parameters with 
7-fold inner CV to select the most predictive regularization parameter. 
Then, the predictive accuracy of the model was evaluated using a 3-fold 
outer CV loop. The nested CV provided an accurate estimate of the 
prediction accuracy on the independent test set.  
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Figure 9: Rank correlation between predicted and observed gene essentiality scores in 
sub-challenge 3. (A) Density distributions of the rank correlations. Red line indicates the 
correlation between the identical genes, and the gray line indicates the correlation 
between the non-identical genes, which is used as a baseline prediction performance 
measure. P values are obtained from a Wilcoxon rank-sum test. (B) Scatterplot of rank 
correlation between predicted gene essentialities and their standard deviations. Genes 
with higher standard deviations had higher prediction accuracy. 
 
 
The final prediction model was based on the best regularization 
parameter learned from the complete training dataset using 7-fold CV.  It 
was found out that the prediction performance of the MT-GRLS did not 
benefit from any prior filtering of the features, perhaps due to its efficient 
feature selection procedure. We evaluated the predictive performance of 
the trained models by rank correlation between the predicted and 
observed gene essentiality profiles. Our MT-GRLS model was the top-
peforming method in the sub-challenge 3, where its average correlation 
for predicted gene essentialities was 0.23, which was significantly higher 
than the baseline correlation observed between the non-identical genes, 
suggesting that genetic datasets have substantial predictive power (Figure 
9A). Further, we observed that individual genes whose essentiality scores 
were more variable across the cell lines were the ones for which predictive 
accuracy was also high, suggesting that each genes feature contributes 
substantially to the overall predictive performance of the models (Figure 
9B). Gene set enrichment analysis revealed that the highly predictable 
genes were enriched for basic cellular processes and functions (Table 2), 
such as proteasome, spliceosome, DNA damage and repair, cell cycle, 
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oxidative phosphorylation and targets of the transcription factors E2F and 
MYC. 
 
 
Gene Set  FDR q-value 
Hallmark Myc targets V1 1.79 ´ 10-20 
KEGG Spliceosome 2.00 ´ 10-17 
KEGG Proteasome 2.98 ´ 10-16 
Hallmark E2F targets 5.44 ´ 10-15 
Hallmark G2M checkpoint 6.13 ´ 10-14 
Hallmark DNA repair 8.82 ´ 10-13 
KEGG Cell cycle 2.16 ´ 10-10 
Hallmark Oxidative phosphorylation 6.71 ´ 10-10 
KEGG Ubiquitin mediated proteolysis 5.58 ´ 10-09 
Hallmark Mitotic spindle 5.58 ´ 10-09 
KEGG Ribosome 5.58 ´ 10-09 
Hallmark MTORC1 signalling 4.22 ´ 10-07 
KEGG Focal adhesion 4.22 ´ 10-07 
KEGG Oocyte meiosis 9.35 ´ 10-07 
Hallmark PI3K-ATK-MTOR signalling 4.69 ´ 10-06 
 
Table 2: Gene set enrichment analysis of the highly predictable genes (rank correlation ³ 
0.4) with MSigDB gene sets from KEGG and Hallmark collection.  
 
 
Moreover, we observed that out of the top 100 features selected for sub-
challenge 3, there were no mutation features and only two features from 
the CNV data, suggesting that gene expression has higher information 
content for gene essentiality prediction, and that CNV and mutation 
profiles may provide partly redundant information. Analysis of the top 100 
features for the sub-challenge 3 provided by the other teams revealed 
that EIF2C2 gene was frequently selected by several prediction models. 
Since EIF2C2 gene is a part of the RNAi machinery, this suggests that the 
expression levels of the components of RNAi machinery can influence the 
phenotypic outcomes of a RNAi screen. Gene set enrichment analysis of 
the top 100 selected features revealed also enrichment for genes involved 
in epithelial-mesenchymal transition, suggesting that cell state 
phenotypic information is predictive of gene essentialities. 
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5.4 Predicting drug response of cancer stem cells using gene 
signatures 
Cancer stem cells are known to exhibit exquisite sensitivity to the small 
molecule inhibitor, salinomycin, however there is a lack of mechanistic 
understanding of its precise mode of action. We reasoned that molecular 
insights gained from experimental studies can be used to derive a gene 
expression signature to predict the response of cancer cells to 
salinomycin, and further aid in identifying groups of patients or tumor 
types that would benefit the most from salinomycin therapy.  
We observed that salinomycin treatment of cells was associated with 
disruption of the KRAS nanoscale membrane organization by altering the 
distribution of phosphatidyl serine (PS), eventually leading to decreased 
signalling output from KRAS nanoclusters due to reduced effector 
recruitment. Moreover, overexpression of caveolin decreased the 
sensitivity of cells to salinomycin by affecting the membrane organization 
(see publication III for details). This suggests that gene expression state of 
known modulators of KRAS nanoscale membrane organization can 
influence the drug response. To gain further insights into the gene 
expression signature associated with KRAS nanoscale membrane 
organization, we utilized the ESTOOLS database (180) to find genes that 
are correlated with its known modulators. Based on the 13 genes that 
were identified, the gene expression signature classified embryonic stem 
cells separately from the fibroblasts, suggesting that the signature was 
also associated with stemness property (Figure 10).  
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Figure 10: Clustering of embryonic stem cells (ESCs) and fibroblasts based on the gene 
expression of known modulators and correlated genes (VIM, ITGA5 and CAV2). Gene 
expression data of Metaset 1 from ESTOOLS database is presented as heatmap. 
 
 
 
Figure 11: Unsupervised clustering of selected cancer cell lines identified as ESC-like and 
fibroblast-like based on correlation with the KRAS nanoclustering associated gene 
expression signature. Gene expression data from CCLE and ESTOOLs were quantile-
normalized and scaled. 
 
To study the stemness property associated with KRAS nanoclustering in 
cancer cells, we further identified cancer cell lines that were correlated 
with gene expression signature of the 13 genes in ESCs and fibroblasts. As 
expected, we observed that the ESC-like cell lines clustered with the ESCs 
and the fibroblast-like cell lines clustered with the fibroblasts (Figure 11). 
Drug sensitivity profiling revealed that the ESC-like cell lines were more 
sensitive to salinomycin whereas less responsive to staurosporine 
compared to fibroblast-like cell lines, suggesting that the gene-expression 
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signature is capable of predicting the stemness property of cancer cell 
lines and also its response to a CSC inhibitor (Figure 12). 
  
 
 
 
Figure 12: Drug response levels of ESC-like and fibroblast-like cancer cell lines to 
salinomycin and staurosporine. Logarithm of IC50 values were obtained from a drug dose 
response curve. p values were obtained by one-side Wilcoxon rank sum test. 
 
 
We further hypothesized that patient tumor samples exhibiting the gene 
expression signature associated with stemness property should present 
differences in their clinical characteristics. To assess that, we performed 
correlation analysis to identify the patient tumor samples in The Cancer 
Genome Atlas (TCGA) dataset that were displaying ESC-like and fibroblast-
like gene expression signature. Interestingly, we found that ESC-like 
patient samples were associated with lower survival probability, when 
compared to non-ESC like samples. As expected, fibroblast-like samples 
did not show the same difference (Figure 13), suggesting that patient 
tumors that are more cancer stem cell like are more aggressive. 
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Figure 13: Survival analysis of patient tumor samples from TCGA, defined as ESC-like (rank 
correlation >= 0.6) and Non ESC-like (rank correlation <= 0.2) and Fibroblast-like like (rank 
correlation >= 0.6) and Non fibroblast-like (rank correlation <= 0.2) based on correlation 
with gene expression signature with ESCs and fibroblasts. 
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6 Discussion  
The rapid advancements in high-throughput techniques have now made 
it possible to molecularly characterize large number of patient tumors, 
and large-scale genomic and functional profiles are routinely being 
generated. Such datasets hold immense potential to reveal novel genes 
driving cancer, biomarkers with prognostic value, and also identify 
promising targets for drug treatment. But the ‘big data’ nature of these 
highly complex datasets require concurrent development of 
computational models and data analysis strategies to be able to mine 
useful knowledge and unlock the potential of the information content that 
is latent in such datasets. This thesis presents computational and 
analytical approaches to extract potentially useful information by 
integrating genomic and functional profiles of cancer cells. 
Publication I demonstrates how in-depth information on the mechanistic 
properties of shRNAs can be utilized to remove noise from genome-wide 
shRNAs screen datasets in post-screening analysis scenario. The study 
particularly aimed to explore means to increase the consistency between 
genome-wide shRNA screens, so that these lessons can be incorporated 
in the designing of future genome wide shRNA screens. Reassuringly, the 
study found moderate consistency between the genome-wide shRNA 
screens, suggesting that although there is a considerable amount of noise 
in the data, it still has the potential to yield promising results. The study 
demonstrated that consistency between shRNA screens is significantly 
higher for the seed mediated off target effects. As observed in a previous 
study [29], we also find that the consistency between datasets increases 
significantly based on seed essentiality scores.  
While it is expected that the specific phenotypic effects of each shRNA 
within a shRNA family might differ in terms of the target profile of down-
regulated off-target genes, averaging overall the constituent shRNAs 
members in a family was found to be indicative of the phenotypic effects 
of the shared off-target profile of genes. This could explain the observed 
increase in consistency between the screens. From the observations 
based on our study, we propose that saturating the seed sequence space 
by sampling over multiple shRNAs having the same seed sequence while 
designing genome wide shRNA libraries is a good approach to accurately 
estimate seed level essentiality scores. This in turn can be used to model 
the off-target genes based on seed sequence complementarity which may 
allow us to derive more accurate gene essentiality scores. Computational 
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methods modelling the seed-mediated effects that have been 
implemented previously to discern the off-target genes in RNAi screens 
(188-191), however their shortcoming is that they are unable to provide 
gene essentiality scores for all genes screened. By focussing on methods 
that can be implemented easily for derivation of gene essentiality 
estimates, this study adopted a simplistic approach by enriching the 
shRNAs with on-target activity.  
From a practical point of view, Publication I provides a straightforward 
approach that can be incorporated in the analysis of existing genome wide 
RNAi screening datasets to extract the most accurate biological 
information out of them. The study identified ‘bad quality’ shRNAs with 
higher propensity of off-target effects based on determinants of targeting 
proficiency of miRNAs, i.e. SPS and TA. Reporter activity studies have 
previously shown that a strong pairing leads to stronger repression of 
bound target and hence proficient down-regulation of off-target 
transcripts [25]. SPS is a measure of the thermodynamic stability [24], a 
proxy for standard free energy change (ΔG) for the formation of the seed 
duplex. Predicted SPS has been calculated after taking into account 
several biochemical parameters and base composition [27]. More 
negative values of free energy change, i.e. stronger SPS, suggests that 
seed duplex is more stable, whereas higher values, i.e. weaker SPS, 
suggest less stable pairing. Further, this study demonstrated the 
quantitative effect of these bad quality shRNAs on the loss of consistency 
of genome-wide shRNA screens. We were able to show that removing the 
bad quality shRNAs from post-processing led to better estimates of gene 
dependency scores using conventional methods for summarizing shRNA 
level scores to gene level essentiality scores. In the future, computational 
models incorporating the biochemical properties of seed sequences 
should be developed to derive more accurate estimates of gene 
essentiality. 
We also demonstrated that performing such post-processing can help in 
identifying novel synthetic lethal partners of cancer driver genes, which 
we also validated using a complementary CRISPR/Cas9 knockout screen. 
One of the important areas of applications of genome-wide RNAi screens 
is to identify dependencies of cancer cells in a certain genetic background 
that can provide interesting targets for anticancer treatment. In 
publication I, we showed how one can extract information on robust 
synthetic lethal interactions partners from noisy genome-wide shRNA 
screens. Moreover, analysing multiple datasets on a large panel of cell 
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lines from diverse lineages and cell types is a useful way to account for the 
genetic heterogeneity known to exist in tumors and identify ‘pan-cancer’ 
synthetic lethal interactions.  
While our approach to identifying synthetic lethal partners is based on the 
conventional viewpoint of differential dependencies in the mutated and 
wild type cell lines, other paradigms for defining synthetic lethal 
interactions also exist. For instance, synthetic dosage lethality is a type of 
genetic interaction in which the upregulation in mRNA or protein levels of 
one partner gene and the loss-of-function of the other partner gene 
results in a lethal phenotype (161). Synthetic lethal interactions are also 
known to be condition-specific, such as being dependent on the cellular 
state, metabolic state, genetic background or tumor microenvironment 
(161). Hence, synthetic lethal interactions observed under laboratory 
conditions in cancer cell lines may not be relevant in the context of overall 
human physiology, and thus clinical responses may not be observed. 
The CRISPR/Cas9 system has recently emerged as an alternative to RNAi 
technology for high-throughput loss-of-function genetic screening. Similar 
to genome-wide RNAi libraries, several genome-wide CRISPR/Cas9 single 
guide RNA (sgRNA) libraries are nowadays available for functional genetic 
screening (192-195). A better understanding of the relative strengths and 
limitations of the two technologies would be of prominent interest to the 
biomedical research community. Evers et al. (196) and Morgens et al. 
(197) recently conducted a systematic comparison by targeting a 
reference set of known essential and non-essential genes to assess the 
relative efficiency of the two approaches; however, the two studies differ 
in their conclusions. The current perspective is shaping up in favor of 
CRISPR-based screens, as these are expected to produce more robust and 
sensitive phenotypes; this view was also supported by the two 
comparative studies, although the Evers study (196) was more positive 
about the superiority of the CRISPR technology, whereas the Morgens 
study (197) concluded that both technologies have their respective 
strengths and limitations. Understanding the factors affecting sgRNA 
activity will be crucial in assessing the relative performance of CRISPR and 
RNAi screens, with the aim at defining the best practices for loss-of-
function screening and designing the most efficient genome-wide sgRNA 
and shRNA libraries. Off-target effects have also been shown in 
CRISPR/Cas9 screens (198), and  several extrinsic factors, such as the 
expression of Cas9 (199), sgRNA sequence properties (200), targeted 
region of protein domains, DNA accessibility and local architecture of the 
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genomic region of the target locus, may also affect the performance of 
CRISPR screens.  
Publication II demonstrated how genomic features of cancer cell lines can 
be used to predict their functional gene essentiality profiles by using 
machine learning models. With the availability of high-throughput 
technologies, it has become easier to profile larger number of tumors and 
generate copious amounts of data representing their molecular 
characteristics. To make sense of these datasets, computational models 
are needed to integrate the multiple layers of information for identifying 
novel ways of treating cancer. The Broad-DREAM gene essentiality 
prediction challenge demonstrated a novel approach in which a 
community effort is leveraged for solving important biomedical questions, 
by establishing benchmark models for prediction tasks. We developed 
MT-GRLS model in sub-challenge 3, demonstrating that the best 
performing method selects sparse panel of genomic features that are 
predictive of gene essentialities of multiple genes. MT-GRLS exploits 
multitask learning, which leverages information that is shared across 
multiple variables, and therefore increases the statistical power of the 
inference problem.  
A consistent finding in publication II was that gene expression data contain 
more predictive information compared to other molecular datasets, as 
has been observed also in other DREAM challenges (169, 201-203). Gene 
expression features were also the most prominently selected top 100 
features in sub-challenge 3. This may reflect the fact that most of the 
predictive models are well suited to incorporate continuous variables, 
whereas extracting predictive information from categorical datatypes, 
such as mutations and copy number variations, has proved more 
challenging for the current models. Analysis of the frequently selected 
gene expression features revealed that expression levels of EIF2C2 has 
significant predictive power of the gene essentiality scores. This suggests 
that the functional state of the RNAi machinery influences the efficiency 
of knockdown and thus the inferred dependency scores. Future predictive 
models should take this into account, and moreover consider that 
genome-wide RNAi screens based phenotypes need to be interpreted 
cautiously. More importantly, this information should be used in post-
processing of genome-wide RNAi screens to estimate accurate gene 
dependency scores. Moreover, the most predictive gene expression 
signatures were enriched for genes involved in epithelial-mesenchymal 
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transition genes indicating that the phenotypic cell state are highly 
informative of the gene essentialities. Perhaps this reflects the previous 
observation that cell lines cluster into two major groups based on gene 
expression data that correspond to the epithelial and mesenchymal 
states.  
The sub-challenge 3 prediction task was restricted to the use of genomic 
and molecular information only, namely mutation, CNV and gene 
expression, which might explain the modest average performance of the 
prediction models. Combining information from multiple other datatypes, 
such as epigenome, proteome, metabolome and other molecular 
portraits of cancer cell lines, could potentially contribute to enhanced 
prediction performance. Also, addition of prior biological knowledge such 
as biological pathways and processes can improve the prediction 
performance, as has been observed previously (169, 174). Moreover, 
systems biology based integrative models that take into account the 
different types of molecular information, and the network and signalling 
properties of genes, can further bring in additional information that are 
predictive of gene essentialities.  
Publication III explored the link between stemness property and 
nanoscale membrane organization of KRAS. Cancer stems cells have been 
linked to EMT transition, and it is likely that KRAS signalling also 
contributes to EMT via Wnt pathway. Additionally, the study 
demonstrates how the mechanistic understanding of affectors of KRAS 
nanoclustering can be coupled with computational analysis of gene 
expression data to build an expression signature predictive of response to 
CSC inhibitors. Importantly, the gene expression signature can also be 
applied in stratifying patients that are more likely to respond to 
salinomycin or other CSC inhibitors. The enrichment of breast cancer 
subtypes in the tumor-types that were ESC-like is in agreement with 
previous studies which identified salinomycin as a CSC inhibitor (142). 
Acute myeloid leukemia cancer-type was also enriched in the ESC-like 
group, corroborating previous results indicating link between stem cell 
expression signature and survival outcomes (204). 
In conclusion, this thesis demonstrates that computational approaches to 
integrate functional and genomic datasets of cancer cell lines can be 
useful in understanding cancer biology and guide further translational 
efforts. Prudent implementation of relevant biological information to the 
analysis of genome-wide RNAi screen datasets can be useful in reducing 
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the noise inherent in these datasets. Ultimately this leads to more 
accurate dependency maps of cancer cells, and therefore may reveal 
potential therapeutic targets for cancer treatment. The study also 
demonstrates that predictive models can be built for gene dependency 
profiling of cancer cell lines. Predictive modelling basd on integrated 
genomic and functional datasets can yield insightful knowledge on the 
molecular characteristics of cancer cells, such as the predictive value of 
EMT phenotype and the biological processes whose dependencies can be 
predicted more accurately. Additionally, the study indicates that the 
transcriptomic landscape has high predictive power for the functional 
landscape of cancer cells. The thesis also demonstrates the power of 
coupling computational approaches with biological hypotheses in 
predicting drug response phenotypes and identifying clinically relevant 
information about patient tumors. 
As a future development, genome-wide loss-of-function screens based on 
complementary CRISPR/Cas9 knockouts will be likely useful in estimating 
more accurate genetic dependencies of cancer cell lines. Computational 
methods to reduce noise in loss-of-function screens, similar to those 
developed in this thesis, should lead to further improvements in accuracy 
of predictive models of gene dependency scores based on genomic 
datasets. Also, incorporating information of proteomic and epigenomic 
landscapes of cancer cell lines could lead to improvement in the predictive 
accuracy of genetic dependencies. Loss-of-function and molecular 
profiling in more advanced cancer cell line models, such as those based on 
3D organoids that recapitulate the tumour features more realistically, may 
further provide better ways to find novel targets. In addition, there is a 
need to develop computational methods that are able to quantitatively 
account for the mechanistic details and several levels of biological 
organization; such as the signalling and pathway level interactions and 
network-level properties of genes and proteins. A holistic systems-biology 
based modelling approach may lead to a better understanding of the 
biology of cancer and will be useful in identifying promising targets for 
cancer treatment.  
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